Endocare Inc. received clearance from the FDA to market its Percutaneous Access Introducer. The device is designed for use with Endocare's Cryocare Surgical System during urological ryosurgery.
Endocare Chairman and CEO Paul Mikus commented, "This introducer device
benefits the patient by enabling physicians to perform cryosurgery more
quickly, with minimal invasion. It also facilitates training of physicians
for this advanced procedure."
About Targeted Cryoablation
Targeted cryoablation, a procedure developed by Endocare, Inc., is the use
of cryoablation (application of extreme cold to destroy tissue) in combination
with ultrasound and temperature monitoring to precisely destroy cancer cells
in and around the prostate gland. Liquefied argon gas, which is contained
within the Cryoprobe tips, freezes and destroys the cancer and tissue that
reaches -40 degrees Celsius. After approximately 10 minutes, the physician
completes the first freeze cycle, then immediately administers another
treatment to help ensure that all cancer cells are killed. The entire
procedure lasts about one to two hours.